The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC).
 
Nobuaki Matsubara
Consulting or Advisory Role - Janssen; Sanofi
Research Funding - Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); MSD (Inst)
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio
Expert Testimony - Celgene; sanofi
 
Hiroyuki Nishiyama
Honoraria - Astellas Pharma
Consulting or Advisory Role - Bayer Yakuhin; Chugai Pharma; Janssen; Lilly; MSD
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Astellas Pharma (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst)
 
Wen-Pin Su
No Relationships to Disclose
 
Jae-Lyun Lee
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai
Research Funding - Bristol-Myers Squibb; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech
 
Jian-Ri Li
No Relationships to Disclose
 
Richard A. Walgren
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Patent applicant/holder, without royalties, for therapeutic applications related to ramucirumab and merestinib. (Inst)
 
Oday Hamid
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Annamaria Zimmermann
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Katherine M Bell-McGuinn
Employment - Lilly
 
Ling Gao
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Gosuke Homma
Employment - Lilly Japan
 
Ikuo Yana
Employment - Lilly Japan
Stock and Other Ownership Interests - Lilly
 
Thomas Powles
Honoraria - Bristol-Myers Squibb; MERCK; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Ipsen